CEO: Lisa Deschamps

Advent Contact: Shahzad Malik

Revolution in gene therapy for neurodegenerative disorders

AviadoBio’s mission is to transform the lives of patients living with and suffering from neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

AviadoBio™ Raises $80 million in Series A Financing to Advance Neurodegenerative Gene Therapy Platform

Back